# Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

> **NCT03784755** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 409 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **RADIATION:** Ablative Radiation Therapy
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT03784755
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-15
- **Primary completion:** 2032-12-31
- **Final completion:** 2033-07-30
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03784755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03784755, "Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03784755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*